PRINCETON, N.J., Jan. 3, 2006 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long-term growth and income-generating focused online investment newsletter, announced today that it has provided subscribers with a detailed look at biotech stocks, including Amgen (Nasdaq:AMGN), Genetech (Nasdaq:DNA), Invitrogen (Nasdaq:IVGN), and Medarex (Nasdaq:MEDX), among others. In-depth coverage of each company can be found in The Bull Market Report archives.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to The Bull Market Report's exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR74
In its report, The Bull Market Report wrote: "Medarex... is a company build on good science, a strong pipeline, and an attractive collection of business relationships with large drug and biotech firms. At the same time that drug companies are facing a need to add biotech products to their stalling chemical-based product lines, the acquisition of Abgenix signals a new willingness among biotechs to buy their partners rather than pay out years of royalties. This won't make sense in every case, but it certainly did for Amgen -- and it could well make sense for Medarex partners, including Bristol-Myers Squibb and Pfizer."
In its coverage, The Bull Market Report looked at the following topics, among others:
-- Will Amgen be able to successfully defend its EPO patents in court against Swiss drug giant Roche?
-- Will Rituxan be an even bigger winner for Genetech in 2006?
-- Will Invitrogen's business with Pfizer improve, or will the drug giant continue to be a challenging customer?
-- Why does Medarex look like such a good takeover candidate?
About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR74
Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook," "Biotech Sector Outlook," and "Understanding the Value of Insider Trading Data."
Note: This release was published by Indie Research, LLC (CRD #131926). Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.